As Regulatory Pathways Are Debated, Tidal Wave Of Biosimilars Can Create A $10 Billion Opportunity By 2015; Indian Companies Aim For Big Gains
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Patent expiries on biotech-based drugs starting in 2012 accompanied with a clearer regulatory framework will throw open a $10 billion market opportunity for biosimilars in the U.S. and Europe; Indian companies including Dr. Reddy's, Intas, Wockhardt and Ranbaxy are all bolstering their product pipelines to prepare for those markets
You may also be interested in...
Sandoz Launches Japan's First Biosimilar; Sees Huge Market Potential In Japan
Novartis's generic subsidiary Sandoz launched recombinant human growth hormone somatropin in Japan. Approved in June with the same indications as Pfizer's Genotropin (somatropin), Sandoz's somatropin marks the first biosimilar launch and the company looks to further generic launches in Japan
Sandoz Launches Japan's First Biosimilar; Sees Huge Market Potential In Japan
Novartis's generic subsidiary Sandoz launched recombinant human growth hormone somatropin in Japan. Approved in June with the same indications as Pfizer's Genotropin (somatropin), Sandoz's somatropin marks the first biosimilar launch and the company looks to further generic launches in Japan
Sandoz Launches Japan's First Biosimilar; Sees Huge Market Potential In Japan
The company plans to launch six to seven new products by the end of the year, and 10 additional products in 2010.